Department of Nuclear Medicine, University Hospital, Zurich, Switzerland.
J Nucl Med. 2010 Apr;51(4):507-10. doi: 10.2967/jnumed.109.071001. Epub 2010 Mar 17.
Our objective was to investigate the use of bowel preparation before (18)F-FDG PET/CT to reduce intestinal (18)F-FDG uptake.
Sixty-five patients with abdominal neoplasias were assigned either to a bowel-preparation group (n = 26) or to a native group (n = 39). (18)F-FDG activity was measured in the small intestine and the colon.
In the 26 patients with bowel preparation, average maximal standardized uptake value (SUVmax) was 3.5 in the small intestine and 4.4 in the colon. In the 39 patients without bowel preparation, average SUVmax was 2.6 in the small intestine and 2.7 in the colon. (18)F-FDG activity impaired diagnosis in 6 patients (23%) in the bowel-preparation group and 11 patients (28%) in the native group (P = 0.5). SUVmax in the colon was significantly higher in the bowel-preparation group (P = 0.002), but SUVmax in the small intestine did not significantly differ between the 2 groups (P = 0.088).
Bowel preparation increases (18)F-FDG activity in the large intestine and is therefore not useful before PET/CT.
研究肠道准备对降低(18)F-FDG PET/CT 中肠道摄取的影响。
65 例腹部肿瘤患者分为肠道准备组(n=26)和自然状态组(n=39)。测量小肠和结肠中的(18)F-FDG 活性。
在 26 例肠道准备患者中,小肠和结肠的平均最大标准化摄取值(SUVmax)分别为 3.5 和 4.4。在 39 例未进行肠道准备的患者中,小肠和结肠的 SUVmax 平均分别为 2.6 和 2.7。肠道准备组 6 例(23%)和自然状态组 11 例(28%)患者的(18)F-FDG 活性影响诊断(P=0.5)。肠道准备组的结肠 SUVmax 明显更高(P=0.002),但两组小肠 SUVmax 无显著差异(P=0.088)。
肠道准备增加大肠中的(18)F-FDG 活性,因此在 PET/CT 前没有用处。